Compare RLMD & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | SLRC |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 777.2M | 803.0M |
| IPO Year | 2012 | 2007 |
| Metric | RLMD | SLRC |
|---|---|---|
| Price | $7.40 | $13.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | $12.40 | ★ $15.14 |
| AVG Volume (30 Days) | ★ 1.1M | 535.6K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.49% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $1.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $42.87 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.44 | $13.25 |
| 52 Week High | $8.00 | $17.20 |
| Indicator | RLMD | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 26.36 |
| Support Level | $6.81 | N/A |
| Resistance Level | $7.94 | $15.60 |
| Average True Range (ATR) | 0.42 | 0.40 |
| MACD | -0.05 | -0.34 |
| Stochastic Oscillator | 51.79 | 2.18 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.